Glucosylceramide Synthase Inhibitor class drugs

4 results

  • cerdelga

    (eliglustat)
    Genzyme Corporation
    CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are categorized as extensive, intermediate, or poor CYP2D6 metabolizers, as determined by an FDA-cleared test. Limitations apply for ultra-rapid metabolizers and indeterminate genotypes.
    Medication Details
    Drug Interactions

  • miglustat

    (MIGLUSTAT)
    ANI Pharmaceuticals, Inc.
    Miglustat is indicated as monotherapy for adult patients with mild to moderate type 1 Gaucher disease when enzyme replacement therapy is not suitable, such as in cases of allergy, hypersensitivity, or poor venous access.
    Medication Details

  • yargesa

    (Miglustat)
    Edenbridge Pharmaceuticals LLC.
    YARGESA is indicated for the treatment of adult patients with mild to moderate Type 1 Gaucher disease as monotherapy when enzyme replacement therapy is not suitable due to reasons such as allergy, hypersensitivity, or poor venous access.
    Medication Details

  • zavesca

    (miglustat)
    Actelion Pharmaceuticals US, Inc.
    ZAVESCA is indicated as monotherapy for treating adult patients with mild to moderate type 1 Gaucher disease when enzyme replacement therapy is not suitable, such as in cases of allergy, hypersensitivity, or poor venous access.
    Medication Details